Search details
1.
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Mol Cancer
; 23(1): 64, 2024 03 26.
Article
in English
| MEDLINE | ID: mdl-38532456
2.
Clinical and genomic landscape of RAS mutations in gynecologic cancers.
Clin Cancer Res
; 2024 Apr 30.
Article
in English
| MEDLINE | ID: mdl-38687597
3.
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.
Clin Cancer Res
; 30(10): 2121-2139, 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38416404
4.
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Sci Rep
; 12(1): 8701, 2022 05 24.
Article
in English
| MEDLINE | ID: mdl-35610322
5.
Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience.
J Hematol
; 11(3): 113-120, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35837373
6.
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience.
J Adv Pract Oncol
; 13(7): 664-672, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-36199491
7.
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Clin Genitourin Cancer
; 20(1): e16-e24, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34362693
8.
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes.
Mol Cancer Res
; 19(3): 395-402, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33323389
9.
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.
ESMO Open
; 5(6): e001073, 2020 11.
Article
in English
| MEDLINE | ID: mdl-33229506
Results
1 -
9
de 9
1
Next >
>>